Two new monoclonalantibodies were approved by the fda in August
elranatamab bcmm, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and, pozelimab bbfg, to treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease The role of recombinant proteins in the fight against cancer and geneticdisorders of the immunesystem has become in recent […]